June 07, 2019
Article
Ruben Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses treating myelofibrosis with ruxolitinib therapy.
Ruben Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the visible symptoms and diagnosis process for patients with myelofibrosis.
June 06, 2019
New trial results show the cytotoxin delivers clinical responses in patients with untreated or relapsed forms of the rare disease.
June 05, 2019
The common, concerning adverse effect requires a careful eye from clinicians and new therapy options.
June 04, 2019
MET inhibitor capmatinib may hold promise for a small subtype of patients with a non-small cell lung cancer, according to new ASCO 2019 findings.
Patients with the rare cancer condition requires both a collaborative physician network and proven therapies.
June 03, 2019
New phase 3 trial results show the monoclonal antibody plus pomalidomide and dexamethasone improves progression free survival and overall response rate among patients with RRMM.
Hu5F9-G4, aided by azacytidine, showed the potential to remove signals on cancer cells that would normally prevent a patient’s body from eliminating said cells.
Phase 3 results show the therapy plus recombinant human hyaluronidase is comparably safe and effective for patients with relapsed-refractory multiple myeloma.
A discussion held at ASCO 2019 highlighted the statistical value associated with primary care collaboration across specialties.
